Literature DB >> 15758252

Short-term effect of bezafibrate on the expression of adiponectin mRNA in the adipose tissues: a study in spontaneously type 2 diabetic rats with visceral obesity.

Yutaka Mori1, Fumiki Oana, Akane Matsuzawa, Satoshi Akahane, Naoko Tajima.   

Abstract

The effect of short-term bezafibrate (BF) administration over time on the expression of adiponectin mRNA in the tissues was examined in Otsuka Long Evans Tokushima Fatty (OLETF) rats. Eight-week-old rats were divided into the high-dose (100 mg/kg) BF group (n=15), the low-dose (10 mg/kg) BF group (n=15), or the control group (n=15) and followed up for 14 d. Tri-glyceride and free fatty acid levels significantly decreased in a dose-dependent manner in the high-dose BF group. The insulin levels increased with time, although they were significantly lower in the high-dose BF group on d 3 and 7 than the control group. Adiponectin levels significantly increased in the high-dose BF group. On d 14 of BF administration, the levels of VLDL and chy-lomicron were significantly lower in BF groups, and adiponectin mRNA expression in the white adipose tissue was significantly higher in the high-dose BF group. Findings from this study suggest that in type 2 diabetes with insulin resistance, hypertriglyceridemia is closely linked to adiponectin.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15758252     DOI: 10.1385/ENDO:25:3:247

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  19 in total

1.  Hyperlipoproteinemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy.

Authors:  M F Mohrschladt; A W Weverling-Rijnsburger; F H de Man; D J Stoeken; A Sturk; A H Smelt; R G Westendorp
Journal:  Atherosclerosis       Date:  2000-02       Impact factor: 5.162

2.  The peroxisome proliferator-activated receptor alpha (PPAR alpha) regulates the plasma thiobarbituric acid-reactive substance (TBARS) level.

Authors:  I Inoue; S Noji; M Z Shen; K Takahashi; S Katayama
Journal:  Biochem Biophys Res Commun       Date:  1997-08-28       Impact factor: 3.575

3.  Lowering of plasma glucose concentrations with bezafibrate in patients with moderately controlled NIDDM.

Authors:  I R Jones; A Swai; R Taylor; M Miller; M F Laker; K G Alberti
Journal:  Diabetes Care       Date:  1990-08       Impact factor: 19.112

4.  Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients.

Authors:  K Hotta; T Funahashi; Y Arita; M Takahashi; M Matsuda; Y Okamoto; H Iwahashi; H Kuriyama; N Ouchi; K Maeda; M Nishida; S Kihara; N Sakai; T Nakajima; K Hasegawa; M Muraguchi; Y Ohmoto; T Nakamura; S Yamashita; T Hanafusa; Y Matsuzawa
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-06       Impact factor: 8.311

5.  Insulin decreases human adiponectin plasma levels.

Authors:  M Möhlig; U Wegewitz; M Osterhoff; F Isken; M Ristow; A F H Pfeiffer; J Spranger
Journal:  Horm Metab Res       Date:  2002 Nov-Dec       Impact factor: 2.936

6.  Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB.

Authors:  Ikuo Inoue; Fumiaki Itoh; Shigemi Aoyagi; Shigeki Tazawa; Hiroshi Kusama; Masuo Akahane; Toshiyuki Mastunaga; Kenji Hayashi; Takuya Awata; Tugikazu Komoda; Sigehiro Katayama
Journal:  Biochem Biophys Res Commun       Date:  2002-01-11       Impact factor: 3.575

7.  Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia.

Authors:  C Weyer; T Funahashi; S Tanaka; K Hotta; Y Matsuzawa; R E Pratley; P A Tataranni
Journal:  J Clin Endocrinol Metab       Date:  2001-05       Impact factor: 5.958

8.  Differential expression of lipoprotein lipase gene in tissues of the rat model with visceral obesity and postprandial hyperlipidemia.

Authors:  M Hikita; H Bujo; K Yamazaki; K Taira; K Takahashi; J Kobayashi; Y Saito
Journal:  Biochem Biophys Res Commun       Date:  2000-10-22       Impact factor: 3.575

9.  Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population.

Authors:  Yukihiro Yamamoto; Hiroshi Hirose; Ikuo Saito; Motowo Tomita; Matsuo Taniyama; Koichi Matsubara; Yasunori Okazaki; Tatsuya Ishii; Kanako Nishikai; Takao Saruta
Journal:  Clin Sci (Lond)       Date:  2002-08       Impact factor: 6.124

10.  Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease.

Authors:  Alexander Tenenbaum; Michael Motro; Enrique Z Fisman; Ehud Schwammenthal; Yehuda Adler; Ilan Goldenberg; Jonathan Leor; Valentina Boyko; Lori Mandelzweig; Solomon Behar
Journal:  Circulation       Date:  2004-05-03       Impact factor: 29.690

View more
  3 in total

1.  Novel PPAR pan agonist, ZBH ameliorates hyperlipidemia and insulin resistance in high fat diet induced hyperlipidemic hamster.

Authors:  Wei Chen; Shiyong Fan; Xinni Xie; Nina Xue; Xueyuan Jin; Lili Wang
Journal:  PLoS One       Date:  2014-04-23       Impact factor: 3.240

2.  Prevention of Elevation in Plasma Triacylglycerol with High-Dose Bezafibrate Treatment Abolishes Insulin Resistance and Attenuates Glucose Intolerance Induced by Short-Term Treatment with Dexamethasone in Rats.

Authors:  Maiara Destro Inácio; Alex Rafacho; Nathália Aparecida de Paula Camaforte; Poliana Teixeira; Priscilla Maria Ponce Vareda; Natália Moretti Violato; José Roberto Bosqueiro
Journal:  Int J Endocrinol       Date:  2018-11-08       Impact factor: 3.257

3.  Aqueous extract of Liriope platyphylla, a traditional Chinese medicine, significantly inhibits abdominal fat accumulation and improves glucose regulation in OLETF type II diabetes model rats.

Authors:  Ji-Eun Kim; In-Sik Hwang; Sun-Il Choi; Hye-Ryun Lee; Young-Ju Lee; Jun-Seo Goo; Hee-Seob Lee; Hong-Ju Son; Min-Ju Jang; Sang-Hak Lee; Byeong-Cheol Kang; Dae-Youn Hwang
Journal:  Lab Anim Res       Date:  2012-09-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.